Loading organizations...
§ Private Profile · 22, Boulevard Bénoni Goullin Nantes, Pays de la Loire 44200, FR
Pherecydes Pharma is a technology company.
Pherecydes Pharma develops precision phage therapy, a biological approach against severe, antibiotic-resistant bacterial infections. The company utilizes specific bacteriophages, naturally occurring viruses, to target and eliminate bacteria, customizing treatments to individual patient infections. This strategy addresses antimicrobial resistance by focusing on key pathogens like Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli.
Founded in 2006, Pherecydes Pharma originated from the critical global health threat posed by antibiotic-resistant bacteria, amidst a decline in new antibiotic discoveries. The company's insight was to harness the natural antibacterial properties of bacteriophages, a long-understood therapeutic avenue, to address this urgent medical need.
Pherecydes Pharma's therapies target patients with severe monobacterial infections unresponsive to traditional antibiotics, including complex conditions such as bone and joint infections. The company aims to provide effective, individualized treatment pathways for these difficult cases, with a vision to establish phage therapy as a standard medical intervention where current options are limited.
Pherecydes Pharma has raised $13.4M across 2 funding rounds.
Pherecydes Pharma has raised $13.4M in total across 2 funding rounds.
Pherecydes Pharma is a biotechnology company specializing in the development of precision phage therapy to treat resistant bacterial infections, particularly those caused by Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Their products leverage bacteriophages—viruses that specifically infect and kill bacteria—to address serious hospital-acquired infections that are increasingly difficult to treat with conventional antibiotics. The company serves healthcare providers and patients facing resistant infections, aiming to offer new therapeutic options where antibiotic resistance limits treatment efficacy. Pherecydes Pharma has demonstrated growth momentum by advancing to clinical trial stages and compassionate use cases under regulatory supervision, reflecting progress in translating phage therapy into practical medical applications[1][2][3].
Founded in 2006, Pherecydes Pharma emerged from a vision to harness bacteriophages as targeted anti-infective agents. The founding team combined expertise from pharmaceutical, biotech, and academic research sectors to pioneer this innovative approach. Early traction included successful compassionate use treatments in 26 patients and the production of pharmaceutical-grade phage batches enabling Phase I/II clinical trials and Early Access Programs by 2021. This progression marked pivotal moments that validated their technology and regulatory acceptance, setting the stage for broader clinical development[1][4].
Pherecydes Pharma rides the growing global trend of addressing antibiotic resistance, a critical and escalating public health challenge. The timing is crucial as traditional antibiotics lose effectiveness, and regulatory agencies increasingly support innovative therapies like phage therapy. Market forces such as rising resistant infections, demand for personalized medicine, and advances in biotechnology favor the adoption of phage-based treatments. By advancing phage therapy, Pherecydes Pharma influences the broader ecosystem by validating bacteriophages as viable therapeutics and encouraging further research and investment in alternative anti-infective technologies[1][3][5].
Pherecydes Pharma is positioned to expand its clinical pipeline and potentially commercialize phage therapies targeting critical resistant infections. Future trends shaping its journey include regulatory acceptance of phage therapy, integration of personalized medicine approaches, and growing global awareness of antibiotic resistance. As clinical data accumulates, the company’s influence may extend beyond niche compassionate use to mainstream therapeutic options, potentially transforming treatment paradigms for resistant bacterial infections. Continued innovation and strategic partnerships will be key to scaling impact and market penetration[1][3][5].
Pherecydes Pharma has raised $13.4M in total across 2 funding rounds.
Pherecydes Pharma's investors include Bpifrance, Go Capital, Karista, Ace Management, Auriga Partners, Fa Di e, Omnes Capital, Participations Besancon.
Pherecydes Pharma has raised $13.4M across 2 funding rounds. Most recently, it raised $2.4M Debt in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 29, 2021 | $2.4M Debt Financing | Bpifrance | — | Announced |
| Jan 1, 2018 | $11M Series B | GO Capital | Karista, ACE Management, Auriga Partners, FA DI E, Omnes Capital, Participations Besancon | Announced |